Related Experiment Videos
Cytogenetic studies in patients on imatinib
1Bone Marrow Transplant/Leukemia Center, Oregon Health and Sciences University, Portland, OR 97239, USA.
Seminars in Hematology
|June 5, 2003
Summary
New imatinib treatments for chronic myeloid leukemia (CML) require re-evaluating diagnostic methods. Cytogenetic remission remains a valid endpoint, but further observation is needed to understand clonal evolution and resistance.
Area of Science:
- Hematology
- Oncology
- Molecular Diagnostics
Background:
- Imatinib (Gleevec) has transformed chronic myeloid leukemia (CML) treatment.
- Conventional cytogenetics was the standard for monitoring interferon-alpha (IFN-alpha) therapy.
- Established endpoints like cytogenetic remission need re-evaluation with imatinib therapy.
Purpose of the Study:
- To assess the validity of diagnostic monitoring methods for CML patients treated with imatinib.
- To explore the prognostic significance of cytogenetic remission and clonal evolution in the imatinib era.
- To investigate novel cytogenetic findings in Ph-negative cells of CML patients in remission.
Main Methods:
- Review of established cytogenetic monitoring protocols for CML.
- Analysis of prognostic value of cytogenetic remission and clonal evolution.
- Observation of Ph-chromosome negative cells for novel karyotypic abnormalities.
Main Results:
- Cytogenetic remission endpoints are likely valid for imatinib therapy, requiring longer observation.
- Cytogenetic remission as a time-dependent variable may improve early risk stratification.
- Clonal evolution provides prognostic information but requires contextual interpretation; it can be linked to imatinib resistance.
Conclusions:
- Diagnostic monitoring for CML must adapt to imatinib therapy.
- Cytogenetic remission and clonal evolution remain crucial prognostic indicators.
- Novel karyotypic abnormalities in Ph-negative cells warrant further investigation for causality and prognostic impact.